Merck says still plans Cubist purchase, despite patent setback

Dec 9 (Reuters) - Merck & Co on Tuesday said it will proceed with its planned $8.4 billion purchase of Cubist Pharmaceuticals and still expects the deal to boost its long-term earnings, despite a court ruling that could speed the arrival of generic forms of Cubist's top-selling product.